Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;200(6):e58-e61.
doi: 10.1111/bjh.18655. Epub 2023 Jan 18.

Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors

Solano de la Asunción Carlos  1 , Estela Giménez  1 , Juan Carlos Hernández-Boluda  2 , María José Terol  2   3 , Eliseo Albert  1 , Javier López-Jiménez  4 , Valentín García-Gutiérrez  4 , Rafael Andreu  5 , Dolores García  6 , María Laura Fox  7 , María José Remigia  2 , Paula Amat  2 , Carlos Solano  2   3 , David Navarro  1   8   9
Affiliations

Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors

Solano de la Asunción Carlos et al. Br J Haematol. 2023 Mar.
No abstract available

Keywords: BCL-2 inhibitors; BCR-ABL1 inhibitors; CMV; CMV DNAemia; CMV T cells; PI-3K inhibitors.

PubMed Disclaimer

References

REFERENCES

    1. Sochacka-Ćwikła A, Mączyński M, Regiec A. FDA-approved drugs for hematological malignancies-the last decade review. Cancers (Basel). 2021;14(1):87.
    1. Ruiz-Camps I, Aguilar-Company J. Risk of infection associated with targeted therapies for solid organ and hematological malignancies. Ther Adv Infect Dis. 2021;8:2049936121989548.
    1. Knoll BM, Seiter K. Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature. Infection. 2018;46(3):409-18.
    1. von Hofsten J, Johnsson Forsberg M, Zetterberg M. Cytomegalovirus retinitis in patient who received Ruxolitinib. N Engl J Med. 2016;374(3):296-7.
    1. Yamauchi K, Inaba T, Colvin HS, Sakakihara I, Yamamoto K, Izumikawa K, et al. Dasatinib-induced colitis: clinical, endoscopic and histological findings. Scand J Gastroenterol. 2022;57(4):449-56.

Publication types